Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE) reported expansion of its global intellectual property portfolio, with 28 issued and 30 pending patents across its precision oncology programs. The WEE1 kinase inhibitor portfolio includes multiple U.S. and international applications and granted patents, with potential patent terms extending to 2047. Lead WEE1 inhibitor APR-1051 is in the ACESOT-1051 Phase 1 trial for advanced/metastatic solid tumors with specific gene alterations.
Aprea’s ATR inhibitor program, including ATRN-119, is protected by four granted U.S. patents, extensive non-U.S. coverage, and pending applications that could extend exclusivity to 2045, plus possible regulatory exclusivities. The ABOYA-119 Phase 1/2a study set an RP2D of 1,100 mg once daily before being closed to prioritize APR-1051, while combination-development options for ATRN-119 are being evaluated.
Positive
- 28 issued and 30 pending patents supporting precision oncology pipeline
- WEE1 patent family, if granted, could extend protection to 2047
- ATR inhibitor estate includes 4 U.S. and 22 non-U.S. granted patents
- ATR granted patents expire 2035–2037, pending could extend to 2045
- Phase 1 trial ongoing for lead WEE1 inhibitor APR-1051
- RP2D of 1,100 mg once daily established for ATRN-119 in 2025
Negative
- ABOYA-119 Phase 1/2a study of ATRN-119 was closed in 2025 to focus on APR-1051
Market Reaction – APRE
Following this news, APRE has gained 2.53%, reflecting a moderate positive market reaction. The stock is currently trading at $0.88. Trading volume is exceptionally heavy at 15.3x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Second-quarter earnings | Positive | +3.5% | Pipeline progress, cash runway, and early APR-1051 activity accompanied quarterly results. |
| Aug 03 | Board appointment mention | Neutral | -3.6% | A board member appointment at Lipocine referenced an existing Aprea director role. |
| Jul 30 | Clinical program update | Positive | +2.3% | Enrollment accelerated and additional combination-regimen development was announced. |
| Jun 01 | Phase 1 clinical data | Positive | -8.6% | Updated data showed early monotherapy activity and manageable tolerability. |
| May 13 | First-quarter earnings | Neutral | -2.2% | Private-placement proceeds and clinical progress accompanied quarterly losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and earnings updates produced mixed 24-hour reactions, including both gains and declines.
Key Terms
wee1 kinase inhibitor medical
atr inhibitor medical
rp2d medical
regulatory exclusivities regulatory
antibody-drug conjugates medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.
“Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “A strong global intellectual property portfolio is a critical component of our strategy, supporting the advancement of potentially best in class oncology therapies while protecting the long-term value of our programs. We remain focused on strengthening our intellectual property position as we advance our pipeline and pursue new treatment options for patients with difficult-to-treat cancers.”
The intellectual property covering Aprea’s WEE1 kinase inhibitor program includes two pending U.S. patent applications, one pending U.S. provisional application, two granted non-U.S. patents (Australia and Korea), and 12 pending non-U.S. patent applications. The WEE1 family of applications, if granted, will expire in 2047, not including any regulatory exclusivities that may be awarded. The WEE1-portfolio covers key aspects of the program, including proprietary compounds, pharmaceutical compositions, and methods of use. The Company’s lead WEE1 inhibitor, APR-1051, is currently being evaluated in the ACESOT-1051 Phase 1 clinical trial in advanced/metastatic solid tumors harboring certain cancer-associated gene alterations.
Aprea’s ATR inhibitor program is protected by a strong patent estate, including four granted U.S. patents, one pending U.S. application, and one pending international application. There are 22 granted non-U.S. patents and 13 pending non-U.S. patent applications. The granted patents will expire 2035-2037 and the pending applications, if granted, could extend exclusivity into 2045. Additional regulatory exclusivities up to five years may also be available. This portfolio comprehensively covers the program’s proprietary compounds, pharmaceutical compositions, and methods of use. During 2025, Aprea determined the recommended Phase 2 monotherapy dose (RP2D) of 1,100 mg once daily for ATRN-119 in the ABOYA-119 Phase 1/2a dose-escalation study and subsequently closed this study to focus resources on the clinical development of APR-1051. Building on the completion of dose escalation, the Company is considering further ATRN-119 development in combination approaches that could expand its therapeutic potential. Aprea believes ATRN-119's mechanism of action, potentially favorable safety profile, and pharmacologic characteristics could make it an ideal candidate for combination with other anti-cancer therapies, including radiation therapy, chemotherapy, antibody-drug conjugates (ADCs) and immune checkpoint inhibitors.
About Aprea
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor and Media Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
